Recombinant protein Ag85B-Rv2660c-MPT70 promotes quality of BCG-induced immune response against <i>Mycobacterium tuberculosis</i> H37Ra.

ABSTRACT:

Introduction

Bacillus Calmette-Guérin (BCG), the only licensed vaccine against Mycobacterium tuberculosis (Mtb) infection, has been extensively used worldwide for over 100 years, but the epidemic of tuberculosis (TB) remains a major challenge to human health and well-being. The quest for a more effective vaccination strategy against the Mtb infection continues. Boosting the protective immunity induced by BCG with recombinant protein is a feasible approach to improve the efficacy of BCG, due to the proven safety and effectiveness of recombinant proteins as vaccination regimes against a variety of infectious diseases. While being shown to be promising in clinical trials in preventing Mtb infection, data suggest this strategy requires further improvement.

Metho

SUBMITTER: Ouyang J 

PROVIDER: S-EPMC11965932 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature